An amyloid β 42-dependent deficit in anandamide mobilization is associated with cognitive dysfunction in Alzheimer's disease

Neurobiology of Aging

Volumn 33, Issue 8, 2012, Pages 1522-1532

  Jung, Kwang Mook ^a   Astarita, Giuseppe ^a   Yasar, Sevil ^b   Vasilevko, Vitaly ^a   Cribbs, David H ^a   Head, Elizabeth ^a   Cotman, Carl W ^a   Piomelli, Daniele ^a,c,d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d ISTITUTO ITALIANO DI TECNOLOGIA   (Italy)

Author keywords

Alzheimer's disease; Amyloid 42; Anandamide; Cognitive dysfunction; Endocannabinoid; Human brain; Lipidomics

Indexed keywords

1 STEAROYL 2 DOCOSAHEXAENOYLGLYCEROPHOSPHOETHANOLAMINE N ARACHIDOYL; 2 ARACHIDONOYLGLYCEROL; AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; AMYLOID PRECURSOR PROTEIN; ANANDAMIDE; MUTANT PROTEIN; TAU PROTEIN; UNCLASSIFIED DRUG;

AGED; ALZHEIMER DISEASE; AMYLOID PLAQUE; ARTICLE; BOSTON NAMING TEST; CLINICAL ARTICLE; COGNITIVE DEFECT; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE ASSOCIATION; FEMALE; FRONTAL CORTEX; HUMAN; HUMAN TISSUE; INFORMATION PROCESSING; KENDRICK DIGIT COPY TEST; LANGUAGE; MALE; MOBILIZATION; NEUROPSYCHOLOGICAL TEST; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; TEMPORAL CORTEX;

AGED; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ARACHIDONIC ACIDS; CADAVER; CEREBRAL CORTEX; COGNITION DISORDERS; FEMALE; HUMANS; LIPID METABOLISM; MALE; PEPTIDE FRAGMENTS; POLYUNSATURATED ALKAMIDES; TISSUE DISTRIBUTION;

EID: 84861859231     PISSN: 01974580     EISSN: 15581497     Source Type: Journal    
DOI: 10.1016/j.neurobiolaging.2011.03.012     Document Type: Article

References (51)

1. Astarita G., Ahmed F., Piomelli D. Identification of biosynthetic precursors for the endocannabinoid anandamide in the rat brain. J. Lipid Res 2008, 49:48-57.
2. Astarita G., Piomelli D. Lipidomic analysis of endocannabinoid metabolism in biological samples. J. Chromatogr. B Anal. Technol. Biomed. Life Sci 2009, 877:2755-2767.
3. Astarita G., Jung K.M., Berchtold N.C., Nguyen V.Q., Gillen D.L., Head E., Cotman C.W., Piomelli D. Deficient liver biosynthesis of docosahexaenoic acid correlates with cognitive impairment in Alzheimer's disease. PLoS One 2010, 5:e12538.
4. Ballesteros-Yáñez I., Valverde O., Ledent C., Maldonado R., DeFelipe J. Chronic cocaine treatment alters dendritic arborization in the adult motor cortex through a CB1 cannabinoid receptor-dependent mechanism. Neuroscience 2007, 146:1536-1545.
5. Benito C., Núñez E., Pazos M.R., Tolón R.M., Romero J. The endocannabinoid system and Alzheimer's disease. Mol. Neurobiol 2007, 36:75-81.
6. Benito C., Núñez E., Tolón R.M., Carrier E.J., Rábano A., Hillard C.J., Romero J. J. Neurosci 2003, 23:11136-11141.
7. Bilkei-Gorzo A., Racz I., Valverde O., Otto M., Michel K., Sastre M., Zimmer A. Early age-related cognitive impairment in mice lacking cannabinoid CB1 receptors. Proc. Natl. Acad. Sci. U. S. A. 2005, 102:15670-15675.
8. Cadas H., Gaillet S., Beltramo M., Venance L., Piomelli D. Biosynthesis of an endogenous cannabinoid precursor in neurons and its control by calcium and cAMP. J. Neurosci 1996, 16:3934-3942.
9. Cadas H., di Tomaso E., Piomelli D. Occurrence and biosynthesis of endogenous cannabinoid precursor, N-arachidonoyl phosphatidylethanolamine, in rat brain. J. Neurosci 1997, 17:1226-1242.
10. Centonze D., Finazzi-Agrò A., Bernardi G., Maccarrone M. The endocannabinoid system in targeting inflammatory neurodegenerative diseases. Trends Pharmacol. Sci 2007, 28:180-187.
11. Chevaleyre V., Takahashi K.A., Castillo P.E. Endocannabinoid-mediated synaptic plasticity in the CNS. Annu. Rev. Neurosci 2006, 29:37-76.
12. Cotman C.W., Anderson A.J. The brain's microenvironment, early functional loss, and the conversion to Alzheimer's disease. Ann. N.Y. Acad. Sci 2000, 924:112-116.
13. Dahlgren K.N., Manelli A.M., Stine W.B., Baker L.K., Krafft G.A., LaDu M.J. Oligomeric and fibrillar species of amyloid-beta peptides differentially affect neuronal viability. J. Biol. Chem 2002, 277:32046-32053.
14. Ehrhart J., Obregon D., Mori T., Hou H., Sun N., Bai Y., Klein T., Fernandez F., Tan J., Shytle R.D. Stimulation of cannabinoid receptor 2 (CB2) suppresses microglial activation. J. Neuroinflammation 2005, 2:29.
15. Folstein M.F., Folstein S.E., McHugh P.R. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J. Psychiatr. Res 1975, 12:189-198.
16. Fraser T., Tayler H., Love S. Fatty acid composition of frontal, temporal and parietal neocortex in the normal human brain and in Alzheimer's disease. Neurochem. Res 2010, 35:503-513.
17. Gandy S. The role of cerebral amyloid beta accumulation in common forms of Alzheimer disease. J. Clin. Invest 2005, 115:1121-1129.
18. Guan Z., Wang Y., Cairns N.J., Lantos P.L., Dallner G., Sindelar P.J. Decrease and structural modifications of phosphatidylethanolamine plasmalogen in the brain with Alzheimer disease. J. Neuropathol. Exp. Neurol 1999, 58:740-747.
19. Gutala R.V., Reddy P.H. The use of real-time PCR analysis in a gene expression study of Alzheimer's disease post-mortem brains. J. Neurosci. Methods 2004, 132:101-107.
20. Haass C., Selkoe D.J. Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid beta-peptide. Nat. Rev. Mol. Cell Biol 2007, 8:101-112.
21. Hashimotodani Y., Ohno-Shosaku T., Kano M. Endocannabinoids and synaptic function in the CNS. Neuroscientist 2007, 13:127-137.
22. Iwatsubo T., Odaka A., Suzuki N., Mizusawa H., Nukina N., Ihara Y. Visualization of A beta 42(43) and A beta 40 in senile plaques with end-specific A beta monoclonals: evidence that an initially deposited species is A beta 42(43). Neuron 1994, 13:45-53.
23. Kaplan E., Goodglass H., Weintraub S. Boston Naming Test 1983, Lee & Febiger, Philadelphia.
24. Katona I., Freund T.F. Endocannabinoid signaling as a synaptic circuit breaker in neurological disease. Nat. Med 2008, 14:923-930.
25. Kendrick D.C. Kendrick Cognitive Tests for the Elderly 1985, NFER-Nelson, Windsor.
26. Lee J.H., Agacinski G., Williams J.H., Wilcock G.K., Esiri M.M., Francis P.T., Wong P.T., Chen C.P., Lai M.K. Intact cannabinoid CB1 receptors in the Alzheimer's disease cortex. Neurochem. Int 2010, 57:985-989.
27. Lever I.J., Robinson M., Cibelli M., Paule C., Santha P., Yee L., Hunt S.P., Cravatt B.F., Elphick M.R., Nagy I., Rice A.S. Localization of the endocannabinoid-degrading enzyme fatty acid amide hydrolase in rat dorsal root ganglion cells and its regulation after peripheral nerve injury. J. Neurosci 2009, 29:3766-3780.
28. Liu J., Wang L., Harvey-White J., Osei-Hyiaman D., Razdan R., Gong Q., Chan A.C., Zhou Z., Huang B.X., Kim H.Y., Kunos G. A biosynthetic pathway for anandamide. Proc. Natl. Acad. Sci. U. S. A. 2006, 103:13345-13350.
29. Lukiw W.J., Cui J.G., Marcheselli V.L., Bodker M., Botkjaer A., Gotlinger K., Serhan C.N., Bazan N.G. A role for docosahexaenoic acid-derived neuroprotectin D1 in neural cell survival and Alzheimer disease. J. Clin. Invest 2005, 115:2774-2783.
30. Lutz B. The endocannabinoid system and extinction learning. Mol. Neurobiol 2007, 36:92-101.
31. Marsicano G., Wotjak C.T., Azad S.C., Bisogno T., Rammes G., Cascio M.G., Hermann H., Tang J., Hofmann C., Zieglgänsberger W., Di Marzo V., Lutz B. The endogenous cannabinoid system controls extinction of aversive memories. Nature 2002, 418:530-534.
32. Mato S., Lafourcade M., Robbe D., Bakiri Y., Manzoni O.J. Role of the cyclic-AMP/PKA cascade and of P/Q-type Ca++ channels in endocannabinoid-mediated long-term depression in the nucleus accumbens. Neuropharmacology 2008, 54:87-94.
33. Mazzola C., Micale V., Drago F. Amnesia induced by beta-amyloid fragments is counteracted by cannabinoid CB1 receptor blockade. Eur. J. Pharmacol 2003, 477:219-225.
34. Mazzola C., Medalie J., Scherma M., Panlilio L.V., Solinas M., Tanda G., Drago F., Cadet J.L., Goldberg S.R., Yasar S. Fatty acid amide hydrolase (FAAH) inhibition enhances memory acquisition through activation of PPAR-alpha nuclear receptors. Learn. Mem 2009, 16:332-337.
35. McGowan E., Pickford F., Kim J., Onstead L., Eriksen J., Yu C., Skipper L., Murphy M.P., Beard J., Das P., Jansen K., Delucia M., Lin W.L., Dolios G., Wang R., Eckman C.B., Dickson D.W., Hutton M., Hardy J., Golde T. Abeta42 is essential for parenchymal and vascular amyloid deposition in mice. Neuron 2005, 47:191-199.
36. Núñez E., Benito C., Tolón R.M., Hillard C.J., Griffin W.S., Romero J. Glial expression of cannabinoid CB(2) receptors and fatty acid amide hydrolase are beta amyloid-linked events in Down's syndrome. Neuroscience 2008, 151:104-110.
37. Okamoto Y., Morishita J., Tsuboi K., Tonai T., Ueda N. Molecular characterization of a phospholipase D generating anandamide and its congeners. J. Biol. Chem 2004, 279:5298-5305.
38. de Oliveira Alvares L., Pasqualini Genro B., Diehl F., Molina V.A., Quillfeldt J.A. Opposite action of hippocampal CB1 receptors in memory reconsolidation and extinction. Neuroscience 2008, 154:1648-1655.
39. Panikashvili D., Simeonidou C., Ben-Shabat S., Hanus L., Breuer A., Mechoulam R., Shohami E. An endogenous cannabinoid (2-AG) is neuroprotective after brain injury. Nature 2001, 413:527-531.
40. Piomelli D., Astarita G., Rapaka R. A neuroscientist's guide to lipidomics. Nat. Rev. Neurosci 2007, 8:743-754.
41. Piomelli D. The molecular logic of endocannabinoid signalling. Nat. Rev. Neurosci 2003, 4:873-884.
42. Prasad K.N., Hovland A.R., La Rosa F.G., Hovland P.G. Prostaglandins as putative neurotoxins in Alzheimer's disease. Proc. Soc. Exp. Biol. Med 1998, 219:120-125.
43. Ramírez B.G., Blázquez C., Gómez del Pulgar T., Guzmán M., de Ceballos M.L. Prevention of Alzheimer's disease pathology by cannabinoids: neuroprotection mediated by blockade of microglial activation. J. Neurosci 2005, 25:1904-1913.
44. Schäbitz W.R., Giuffrida A., Berger C., Aschoff A., Schwaninger M., Schwab S., Piomelli D. Release of fatty acid amides in a patient with hemispheric stroke: a microdialysis study. Stroke 2002, 33:2112-2114.
45. Schmid P.C., Krebsbach R.J., Perry S.R., Dettmer T.M., Maasson J.L., Schmid H.H. Occurrence and postmortem generation of anandamide and other long-chain N-acylethanolamines in mammalian brain. FEBS Lett 1995, 375:117-120.
46. Skinner E.R., Watt C., Besson J.A., Best P.V. Differences in the fatty acid composition of the grey and white matter of different regions of the brains of patients with Alzheimer's disease and control subjects. Brain 1993, 116:717-725.
47. Söderberg M., Edlund C., Kristensson K., Dallner G. Fatty acid composition of brain phospholipids in aging and in Alzheimer's disease. Lipids 1991, 26:421-425.
48. Solorzano C., Zhu C., Battista N., Astarita G., Lodola A., Rivara S., Mor M., Russo R., Maccarrone M., Antonietti F., Duranti A., Tontini A., Cuzzocrea S., Tarzia G., Piomelli D. Selective N-acylethanolamine-hydrolyzing acid amidase inhibition reveals a key role for endogenous palmitoylethanolamide in inflammation. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:20966-20971.
49. van der Stelt M., Mazzola C., Esposito G., Matias I., Petrosino S., De Filippis D., Micale V., Steardo L., Drago F., Iuvone T., Di Marzo V. Endocannabinoids and beta-amyloid-induced neurotoxicity in vivo: effect of pharmacological elevation of endocannabinoid levels. Cell. Mol. Life Sci 2006, 63:1410-1424.
50. Thinakaran G., Teplow D.B., Siman R., Greenberg B., Sisodia S.S. Metabolism of the "Swedish" amyloid precursor protein variant in neuro2a (N2a) cells. Evidence that cleavage at the "beta-secretase" site occurs in the golgi apparatus. J. Biol. Chem 1996, 271:9390-9397.
51. Varvel S.A., Wise L.E., Niyuhire F., Cravatt B.F., Lichtman A.H. Inhibition of fatty-acid amide hydrolase accelerates acquisition and extinction rates in a spatial memory task. Neuropsychopharmacology 2007, 32:1032-1041.